OXLUMO® - PANTHERx Rare

OXLUMO® (lumasiran)
www.oxlumo.com

OXLUMO® (lumasiran) is FDA-approved for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients.

Resources

Alnylam: Primary Hyperoxaluria EXPLORE

Alnylam: Patient Advocacy EXPLORE

Clinical Manifestations of PH1 EXPLORE

Lumasiran Fact Sheet EXPLORE

Managing PH1 EXPLORE

Testing for PH1 EXPLORE

Alnylam Assist® Online Start Form EXPLORE

National Institutes of Health: Genetic & Rare Diseases Information Center EXPLORE

NORD (National Organization for Rare Disorders) EXPLORE

Oxalosis & Hyperoxaluria Foundation EXPLORE

PH1 Support EXPLORE

Rare Kidney Stone Consortium EXPLORE

Rare Renal: Hyperoxaluria EXPLORE

PANTHERx Rare Contact

833-706-0702

Manufacturer Contact

Alnylam
https://www.alnylam.com/
833.256.2748

7x Winner of the MMIT Patient Choice Award!

Give us a call 855.726.8479 | 412.246.9858

Primary Hyperoxaluria Type 1 (PH1)

Resources

PANTHERx Rare Contact

Manufacturer Contact